Brind.
  1. IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.
  2. IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform.

Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025.

Who's involved

What this event is mainly about
IDEXX Laboratories, Inc.

How it developed

Newest first. Tap a step to see who reported it.
  1. FMT and HST contributed $310.9 million and $365.3 million, respectively, to Idex's net sales on July 30, 2025.Sub-event
  2. IDEXX achieved profitability due to revenue growth.1 source

Keep exploring

Part of

IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform. All 1 developments

Within IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.IDEXX Laboratories Second Quarter 2025 Earnings: Beats Expectations Explore IDEXX Laboratories's Fair Values from the Community and select yours Revenue: US$1.11b (up 11% from 2Q 2024). Net income: